![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
(HepDart) PREVALENCE AND IMPACT OF BASELINE NS5A RESISTANCE ASSOCIATED VARIANTS (RAVS) IN HCV GT1A PATIENTS TREATED WITH ELBASVIR/GRAZOPREVIR (EBR/GZR)
|
|
|
Reported by Jules Levin
HepDART, Wailea, HI. Dec 6-10, 2015
Ernest Asante-Appiah, Ira Jacobsen, Peggy Wong, Todd Black, Anita Howe, Janice Wahl, Michael N. Robertson, Bach-Yen Nguyen, Melissa Shaughnessy, Peggy Hwang, Eliav Barr and Daria Hazuda
AASLD: Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks - (11/23/15)
AASLD: AN INTEGRATED ANALYSIS OF 402 COMPENSATED CIRRHOTIC PATIENTS WITH HCV GENOTYPE (GT) 1, 4 or 6 INFECTION TREATED WITH Elbasvir/GRAZOPREVIR - (11/19/15)
AASLD: Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting® - (11/18/15)
AASLD: Eliminate Restrictions to Substance Users/Injection Drug Users - SVR Rates the Same in New Study as in Non-IDUs 96% - Routine HCV Testing is needed - (11/18/15)
AASLD: C-EDGE CO-STAR: efficacy of grazoprevir / elbasvir Fixed Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy - (11/16/15)
AASLD: Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy - (11/18/15)
AASLD: Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting® - (11/19/15)
AASLD: Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 1nfection (Part A of C-CREST-1 & 2) - (11/23/15)
AASLD: C-EDGE Co-Infected: final results from Phase 3 Study of elbasvir / grazoprevir in Patients with HCV/HIV - (11/30/15)
![AASLD1.gif](../images/122215/122215-9/AASLD1.gif)
![AASLD2.gif](../images/122215/122215-9/AASLD2.gif)
![AASLD3.gif](../images/122215/122215-9/AASLD3.gif)
![AASLD4.gif](../images/122215/122215-9/AASLD4.gif)
![AASLD5.gif](../images/122215/122215-9/AASLD5.gif)
![AASLD6.gif](../images/122215/122215-9/AASLD6.gif)
![AASLD7.gif](../images/122215/122215-9/AASLD7.gif)
![AASLD8.gif](../images/122215/122215-9/AASLD8.gif)
![AASLD9.gif](../images/122215/122215-9/AASLD9.gif)
![AASLD10.gif](../images/122215/122215-9/AASLD10.gif)
![AASLD11.gif](../images/122215/122215-9/AASLD11.gif)
![AASLD12.gif](../images/122215/122215-9/AASLD12.gif)
![AASLD13.gif](../images/122215/122215-9/AASLD13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|